Artificial Intelligence in Mammography Screening in Norway
Recruiting now · Not applicable
Conditions studied: Breast Cancer
In brief
The purpose of this randomized controlled trial is to compare the number of breast cancers detected among women who had their screening mammograms interpreted by artificial intelligence (AI) in combination with one or two breast radiologists to the number of breast cancers detected after standard independent double reading in BreastScreen Norway. The aims of the study is to prove that screening interpretation with AI in combination with one or two radiologists (the intervention) is non-inferior to standard interpretation procedure.
Key facts
- Study ID
- NCT06032390
- Run by
- Norwegian Institute of Public Health
- People needed
- 150000
- Starts
- 2024-11-25
- Expected to finish
- 2033-06-01
- Last updated by the study team
- 2026-01-14
Who can join
Age: 50 and older, up to 69. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Women attending the population-based mammography screening program BreastScreen Norway providing a signed, informed consent
You may not qualify if…
- Women attending the population-based mammography screening program BreastScreen Norway not providing a signed, informed consent
Where it is running
- Cancer Registry of Norway, Norwegian Institute of Public Health — Oslo, Norway (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.